Core Viewpoint - Inventiva, a clinical-stage biopharmaceutical company, is set to release its 2025 full-year financial results on March 30, 2026, after market close in the United States [1]. Group 1: Financial Results Announcement - The company will announce its 2025 full-year financial results on March 30, 2026 [1]. - A conference call will be held on March 31, 2026, at 8:00 am (New York) and 2:00 pm (Paris) to discuss the results [2]. - Participants must register in advance to join the conference call and ask questions [2]. Group 2: Company Overview - Inventiva focuses on developing oral small molecule therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs [4]. - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for treating adult patients with MASH [4]. - Inventiva is publicly listed on Euronext Paris and the Nasdaq Global Market under the ticker IVA [5].

Core Insights - Inventiva, a clinical-stage biopharmaceutical company, focuses on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] Group 1: Corporate Overview - CEO Andrew Obenshain will present a corporate overview and engage in investor meetings at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026 [1] - The presentation is scheduled for January 15, 2026, from 9:00 am to 9:40 am (PST) at The Westin St. Francis Hotel, San Francisco, California [2] Group 2: Product Development - Inventiva is evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for treating adult patients with MASH [2]

Core Insights - Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) [1][3] - The company will participate in the Canaccord Genuity 45th Annual Growth Conference, highlighting updates on lanifibranor and the Phase III NATiV3 trial [2][3] Company Overview - Inventiva is listed on Euronext Paris and NASDAQ, focusing on oral small molecule therapies for MASH and other diseases with significant unmet medical needs [3][4] - The company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in a pivotal Phase 3 clinical trial for adult patients with MASH [3]